GlassScriptPhysician profile
Brad Michael Burns
NPI 1437783545
$3,037.36
in general payments reported to CMS, 2019-2025
16 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $40.74 · 2023: $1,064 · 2024: $743 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,996.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $725.63 | 2023-2024 | Rukobia, Apretude |
| Alkermes, INC. | $617.99 | 2023-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $500.29 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $298.39 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $259.72 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Janssen Biotech, INC. | $154.29 | 2023 | Symtuza |
| Teva Pharmaceuticals USA, INC. | $145.63 | 2024-2025 | Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $127.61 | 2023 | Auvelity |
| Neurocrine Biosciences, INC. | $64.75 | 2025 | |
| Gilead Sciences, INC. | $33.72 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $19.70 | 2024 | Cobenfy |
| Merck Sharp & Dohme LLC | $19.49 | 2024 | Delstrigo, Pifeltro |
| Antares Pharma, INC. | $18.75 | 2024 | Xyosted |
| Halozyme INC | $18.25 | 2023 | |
| Indivior INC. | $17.08 | 2023 | Perseris |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $16.07 | 2023 | Trogarzo, Egrifta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.